Merck & Co. Inc. (MRK)

$ 102.32
   
  • Change Today:
    $-2.51
  • 52 Week High: $132.96
  • 52 Week Low: $98.60
  • Currency: US Dollars
  • Shares Issued: 2,531.63m
  • Volume: 17,413,051
  • Market Cap: $259,037m
  • RiskGrade: 92

Merck to buy drug targeting B-cell diseases for up to $1.3bn

By Michele Maatouk

Date: Friday 09 Aug 2024

LONDON (ShareCast) - (Sharecast News) - Merck said on Friday that it has agreed to buy biotech firm Curon's CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, for up to $1.3bn.
Under the terms of the deal, Merck will buy full global rights to CN201 for an upfront cash payment of $700m. Curon is also eligible to receive up to $600m in milestone payments associated with the development and regulatory approval of CN201.

Dr. Dean Y. Li, president of Merck Research Laboratories, said: "We continue to identify opportunities to expand and diversify our pipeline.

"Early clinical data have provided robust evidence for the potential of CN201 to target and deplete circulating and tissue B cells with the potential to treat a range of malignant and autoimmune diseases."

CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively.

Merck said preliminary data suggest CN201 has activity in patients with relapsed or refractory B-cell hematologic malignancies and is well tolerated, with the potential to induce significant and sustained reductions in B-cell populations.

Merck plans to evaluate CN201 as a treatment for B-cell malignancies as well as investigate its potential to provide a novel, scalable option for the treatment of autoimmune diseases.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Merck Market Data

Currency US Dollars
Share Price $ 102.32
Change Today $ -2.51
% Change -2.39 %
52 Week High $132.96
52 Week Low $98.60
Volume 17,413,051
Shares Issued 2,531.63m
Market Cap $259,037m
RiskGrade 92

What The Brokers Say

Strong Buy 11
Buy 11
Neutral 3
Sell 0
Strong Sell 0
Total 25
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 31-Oct-2024

Time Volume / Share Price
16:00 1,954,517 @ $102.32
15:59 117 @ $102.31
15:59 191 @ $102.31
15:59 326 @ $102.31
15:59 127 @ $102.32

Top of Page